- Previous Close
2,284.00 - Open
2,256.00 - Bid 2,290.00 x --
- Ask 2,292.00 x --
- Day's Range
2,256.00 - 2,295.00 - 52 Week Range
1,760.50 - 2,295.00 - Volume
54,631 - Avg. Volume
69,299 - Market Cap (intraday)
5.086B - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
3,321.74 - EPS (TTM)
0.69 - Earnings Date Feb 26, 2025
- Forward Dividend & Yield 0.62 (2.69%)
- Ex-Dividend Date Aug 15, 2024
- 1y Target Est
--
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
www.hikma.com9,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HIKL.XC
View MorePerformance Overview: HIKL.XC
Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HIKL.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HIKL.XC
View MoreValuation Measures
Market Cap
5.09B
Enterprise Value
5.86B
Trailing P/E
33.50
Forward P/E
12.58
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.20
Price/Book (mrq)
2.87
Enterprise Value/Revenue
2.53
Enterprise Value/EBITDA
13.19
Financial Highlights
Profitability and Income Statement
Profit Margin
9.45%
Return on Assets (ttm)
9.40%
Return on Equity (ttm)
12.88%
Revenue (ttm)
3.02B
Net Income Avi to Common (ttm)
285M
Diluted EPS (ttm)
0.69
Balance Sheet and Cash Flow
Total Cash (mrq)
260M
Total Debt/Equity (mrq)
55.48%
Levered Free Cash Flow (ttm)
410.38M